United Therapeutics Free Cash Flow Per Share Growth & History (UTHR)
United Therapeutics's free cash flow per share was $23.49 for fiscal 2025.
View full United Therapeutics company overviewUnited Therapeutics annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $23.49 | -$0.41 | −1.74% |
| 2024 | 2024-12-31 | $23.91 | $7.93 | +49.66% |
| 2023 | 2023-12-31 | $15.97 | $1.39 | +9.51% |
| 2022 | 2022-12-31 | $14.59 | $3.95 | +37.19% |
| 2021 | 2021-12-31 | $10.63 | -$5.12 | −32.52% |
| 2020 | 2020-12-31 | $15.76 | $22.38 | — |
| 2019 | 2019-12-31 | -$6.63 | -$20.28 | — |
| 2018 | 2018-12-31 | $13.66 | $4.84 | +54.89% |
| 2017 | 2017-12-31 | $8.82 | -$5.01 | −36.24% |
| 2016 | 2016-12-31 | $13.83 | $6.59 | +91.00% |
| 2015 | 2015-12-31 | $7.24 | $0.85 | +13.32% |
| 2014 | 2014-12-31 | $6.39 | -$1.47 | −18.68% |
| 2013 | 2013-12-31 | $7.86 | $3.79 | +93.27% |
| 2012 | 2012-12-31 | $4.06 | $0.32 | +8.46% |
| 2011 | 2011-12-31 | $3.75 | $0.31 | +9.07% |
| 2010 | 2010-12-31 | $3.44 | $3.35 | +4137.23% |
| 2009 | 2009-12-31 | $0.08 | $3.68 | — |
| 2008 | 2008-12-31 | -$3.60 | — | — |
United Therapeutics quarterly free cash flow per share
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.83 | $1.95 | +68.08% |
| Q1 2026 | 2026-03-31 | $8.33 | -$0.27 | −3.14% |
| Q4 2025 | 2025-12-31 | $4.00 | — | — |
| Q3 2025 | 2025-09-30 | $8.03 | $1.29 | +19.06% |
| Q2 2025 | 2025-06-30 | $2.87 | -$1.34 | −31.86% |
| Q1 2025 | 2025-03-31 | $8.60 | $1.41 | +19.53% |
| Q3 2024 | 2024-09-30 | $6.74 | $0.76 | +12.73% |
| Q2 2024 | 2024-06-30 | $4.21 | $2.90 | +220.84% |
| Q1 2024 | 2024-03-31 | $7.20 | -$0.01 | −0.07% |
| Q3 2023 | 2023-09-30 | $5.98 | $1.81 | +43.38% |
| Q2 2023 | 2023-06-30 | $1.31 | -$1.11 | −45.79% |
| Q1 2023 | 2023-03-31 | $7.20 | $1.11 | +18.31% |
| Q3 2022 | 2022-09-30 | $4.17 | $0.56 | +15.40% |
| Q2 2022 | 2022-06-30 | $2.42 | -$0.52 | −17.71% |
| Q1 2022 | 2022-03-31 | $6.09 | $4.31 | +242.86% |
| Q3 2021 | 2021-09-30 | $3.61 | -$1.68 | −31.73% |
| Q2 2021 | 2021-06-30 | $2.94 | -$0.36 | −10.95% |
| Q1 2021 | 2021-03-31 | $1.78 | -$2.82 | −61.33% |
| Q3 2020 | 2020-09-30 | $5.30 | $1.38 | +35.30% |
| Q2 2020 | 2020-06-30 | $3.31 | $0.74 | +28.60% |
| Q1 2020 | 2020-03-31 | $4.59 | $19.52 | — |
| Q3 2019 | 2019-09-30 | $3.91 | -$0.58 | −12.95% |
| Q2 2019 | 2019-06-30 | $2.57 | -$0.36 | −12.27% |
| Q1 2019 | 2019-03-31 | -$14.93 | -$20.43 | — |
| Q3 2018 | 2018-09-30 | $4.50 | -$0.95 | −17.50% |
| Q2 2018 | 2018-06-30 | $2.93 | $1.82 | +164.21% |
| Q1 2018 | 2018-03-31 | $5.50 | $0.66 | +13.71% |
| Q3 2017 | 2017-09-30 | $5.45 | $0.37 | +7.20% |
| Q2 2017 | 2017-06-30 | $1.11 | -$1.49 | −57.39% |
| Q1 2017 | 2017-03-31 | $4.84 | $2.15 | +79.96% |
| Q3 2016 | 2016-09-30 | $5.08 | $0.76 | +17.59% |
| Q2 2016 | 2016-06-30 | $2.60 | $1.80 | +222.54% |
| Q1 2016 | 2016-03-31 | $2.69 | $0.44 | +19.40% |
| Q3 2015 | 2015-09-30 | $4.32 | $0.20 | +4.91% |
| Q2 2015 | 2015-06-30 | $0.81 | $2.22 | — |
| Q1 2015 | 2015-03-31 | $2.25 | $0.43 | +23.40% |
| Q3 2014 | 2014-09-30 | $4.12 | $1.52 | +58.67% |
| Q2 2014 | 2014-06-30 | -$1.41 | -$3.00 | — |
| Q1 2014 | 2014-03-31 | $1.82 | -$0.04 | −2.02% |
| Q3 2013 | 2013-09-30 | $2.60 | $0.91 | +54.27% |
| Q2 2013 | 2013-06-30 | $1.59 | $0.76 | +91.29% |
| Q1 2013 | 2013-03-31 | $1.86 | $1.91 | — |
| Q3 2012 | 2012-09-30 | $1.68 | $0.61 | +56.24% |
| Q2 2012 | 2012-06-30 | $0.83 | -$0.06 | −7.19% |
| Q1 2012 | 2012-03-31 | -$0.05 | -$0.86 | — |
| Q3 2011 | 2011-09-30 | $1.08 | -$0.67 | −38.31% |
| Q2 2011 | 2011-06-30 | $0.89 | $0.31 | +54.21% |
| Q1 2011 | 2011-03-31 | $0.81 | $0.31 | +60.05% |
| Q3 2010 | 2010-09-30 | $1.75 | $1.90 | — |
| Q2 2010 | 2010-06-30 | $0.58 | — | — |
| Q1 2010 | 2010-03-31 | $0.51 | — | — |
| Q3 2009 | 2009-09-30 | -$0.15 | — | — |
United Therapeutics free cash flow per share trends
Over the last five fiscal years, United Therapeutics's free cash flow per share increased from $15.76 to $23.49, a change of $7.74. The latest reported quarter, Q2 2026, shows $4.83.
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review United Therapeutics source filings ↗